Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Kelderman, S.; Heemskerk, B.; Tinteren, H. van; Brom, R.R.H. van den; Hospers, G.A.P.; Eertwegh, A.J.M. van den; ... ; Blank, C.U. (2014)

Article / Letter to editor

• Melanoma
• Immunotherapy
• Ipilimumab
• Lactate dehydrogenase
• Biomarker

• All authors: Kelderman, S.; Heemskerk, B.; Tinteren, H. van; Brom, R.R.H. van den; Hospers, G.A.P.; Eertwegh, A.J.M. van den; Kapiteijn, E.W.; Groot, J.W.B. de; Soetekouw, P.; Jansen, R.L.; Fiets, E.; Furness, A.J.S.; Renn, A.; Krzystanek, M.; Szallasi, Z.; Lorigan, P.; Gore, M.E.; Schumacher, T.N.M.; Haanen, J.B.A.G.; Larkin, J.M.G.; Blank, C.U.
• Date: 2014-05-31
• Journal: Cancer Immunology, Immunotherapy
• Volume: 63
• Issue: 5
• Pages: 449 - 458
• DOI: doi:10.1007/s00262-014-1528-9